2-氟-1-碘-4-甲氧基苯 | 458-51-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-氟-1-碘-4-甲氧基苯
• 英文名称: 2-fluoro-1-iodo-4-methoxybenzene
• CAS: 458-51-5
• 化学式: C₇H₆FIO
• 分子量: 252.027
• InChiKey: CGSWCMRVWKVUSA-UHFFFAOYSA-N

物化性质

• 沸点：
  223.1±25.0 °C(Predicted)
• 密度：
  1.803±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-氟-1-碘-4-甲氧基苯 在 盐酸 、 sodium tetrahydroborate 、 potassium chloride 、 四丁基醋酸铵 、 palladium diacetate 、 三溴化磷 、 potassium carbonate 作用下， 以 甲醇 、 乙醚 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.17h， 生成 1-(3-Bromoprop-1-en-1-yl)-2-fluoro-4-methoxybenzene
  参考文献：
  名称：

  Novel Inhibitors of Staphyloxanthin Virulence Factor in Comparison with Linezolid and Vancomycin versus Methicillin-Resistant, Linezolid-Resistant, and Vancomycin-Intermediate Staphylococcus aureus Infections in Vivo

  摘要：

  Our previous work (Wang et al. J. Med. Chem. 2016, 59, 4831-4848) revealed that effective benzocycloalkane-derived staphyloxanthin inhibitors against methicillin-resistant Staphylococcus aureus (S. aureus) infections were accompanied by poor water solubility and high hERG inhibition and dosages (preadministration). In this study, 92 chroman and coumaran derivatives as novel inhibitors have been addressed for overcoming deficiencies above. Derivatives 69 and 105 displayed excellent pigment inhibitory activities and low hERG inhibition, along with improvement of solubility by salt type selection. The broad and significantly potent antibacterial spectra of 69 and 105 were displayed first with normal administration in the livers and hearts in mice against pigmented S. aureus Newman, Mu50 (vancomycin-intermediate S. aureus), and NRS271 (linezolid-resistant S. aureus), compared with linezolid and vancomycin. In summary, both 69 and 105 have the potential to be developed as good antibacterial candidates targeting virulence factors.

  DOI：

  10.1021/acs.jmedchem.7b00949
• 作为产物：
  描述：

  3-氟-4-硝基苯甲醚 在 铁粉 、 溶剂黄146 作用下， 生成 2-氟-1-碘-4-甲氧基苯
  参考文献：
  名称：

  Hodgson; Nixon, Journal of the Chemical Society, 1931, p. 981

  摘要：

  DOI：

文献信息

• [EN] PIPERIDINES OR PIPERIDONES SUBSTITUTED WITH UREA AND PHENYL<br/>[FR] PIPÉRIDINES OU PIPÉRIDONES SUBSTITUÉES PAR DE L'URÉE ET DU PHÉNYLE
  申请人：GRUENENTHAL GMBH

  公开号：WO2019170904A1

  公开（公告）日：2019-09-12

  The present invention relates to a compound according to general formula (I) which acts as a modulator of FPR2 and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by FPR2.

  本发明涉及一种符合一般式（I）的化合物，该化合物作为FPR2的调节剂，并可用于治疗和/或预防至少部分由FPR2介导的疾病。
• [EN] COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR LE TRAITEMENT DE MALADIES PARASITAIRES
  申请人：IRM LLC

  公开号：WO2014078813A1

  公开（公告）日：2014-05-22

  The present invention provides compounds of formula I: [INSERT FORMULA HERE] or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease, such as malaria, caused by a Plasmodium parasite.

  本发明提供了式I的化合物：[在此插入公式]或其药学上可接受的盐、互变异构体或立体异构体，其中变量如本文所定义。本发明还提供了包含这种化合物的药物组合物以及使用这种化合物治疗、预防、抑制、改善或根除由疟原虫引起的疟疾等疾病的方法。
• [EN] COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND USES THEREOF IN MEDICINE<br/>[FR] COMPOSÉS EN TANT QU'INHIBITEURS DU VIRUS DE L'HÉPATITE C (VHC) ET LEURS UTILISATIONS EN MÉDECINE
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2015197028A1

  公开（公告）日：2015-12-30

  Provided herein are compounds of Formula (I), or a stereoisomer, a geometric isomer, an enantiomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which are used in the treatment of HCV infection or hepatitis C. Provided herein also are pharmaceutical compositions containing such compounds and methods of using the compound of the present invention or pharmaceutical compositions thereof to treat HCV infection or hepatitis C.

  本文提供了式（I）的化合物，或其立体异构体、几何异构体、对映体、互变异构体、N-氧化物、水合物、溶剂合物、代谢物、药学上可接受的盐或其前药，用于治疗HCV感染或丙型肝炎。本文还提供了含有这些化合物的药物组合物以及使用本发明的化合物或其药物组合物治疗HCV感染或丙型肝炎的方法。
• [EN] PYRROLIDINE GPR40 MODULATORS<br/>[FR] MODULATEURS PYRROLIDINES DE GPR40
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014078609A1

  公开（公告）日：2014-05-22

  The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

  本发明提供了式(I)的化合物：或其立体异构体，或其药物可接受的盐，其中所有变量均如本文所述定义。这些化合物是GPR40 G蛋白偶联受体的调节剂，可用作药物。
• Regioselective SNAr reactions of substituted difluorobenzene derivatives: practical synthesis of fluoroaryl ethers and substituted resorcinols
  作者：Stéphane G. Ouellet、Anna Bernardi、Remy Angelaud、Paul D. O’Shea

  DOI：10.1016/j.tetlet.2009.03.204

  日期：2009.7

  In this Letter, we describe a practical and highly selective method for the preparation of fluoroaryl ethers and differentially substituted resorcinol derivatives. This synthetic strategy relies on a selective SNAr of substituted difluorobenzene derivatives with various alcohols.

  在这封信中，我们描述了一种实用且高度选择性的方法，用于制备氟代芳基醚和差异取代的间苯二酚衍生物。该合成策略依赖于取代的二氟苯衍生物与各种醇的选择性S N Ar。